Q fever is a bacterial disease that can spread from infected animals, particularly cattle, sheep and goats, to humans. People can become infected by breathing in contaminated dust or particles from animal environments. The illness can cause severe flu-like symptoms, including fever, headaches, muscle pain and extreme tiredness. Some patients develop long-term complications, including serious cardiovascular problems.

Australia recorded 991 Q fever cases in 2025, the highest annual total since national monitoring began in 1991. The figures highlight the continuing public health importance of preventing the disease, particularly in rural communities and industries involving livestock.

The vaccine, known as Q-VAX, is manufactured by CSL Seqirus under an agreement with the Australian Department of Health. The company has confirmed that unexpected manufacturing difficulties and raw-material supply problems have disrupted production.

CSL Seqirus senior vice-president of operations Chris Larkins said several vaccine batches could not be released into the market. The manufacturing process is particularly complex because each batch takes approximately nine months to produce.

The company expects the next two batches to become available in late December 2026. It has also said that improving production reliability is a priority because of the vaccine's importance to public health and agricultural businesses.

The shortage is already affecting farms. Erika Chesworth, who operates Little Big Dairy near Dubbo in New South Wales, said she had been unable to vaccinate new employees since March because local clinics could not obtain supplies.

She explained that the situation was creating additional difficulties for agricultural businesses that depend on trained workers. Her farm had previously experienced cases in which employees became seriously ill with Q fever.

The shortage also affects workers outside dairy farming. Meat-processing employees, livestock handlers, shearers and others who regularly work around animals may face exposure risks. Some workplaces have vaccination requirements because of the nature of their operations.

Nurse and shearer Carol Mudford said accessing vaccination had been difficult for several years. She has called for greater public awareness, noting that people living in rural areas may face exposure even if they do not work directly with livestock.

The Australian Department of Health said CSL Seqirus was responsible for managing vaccine manufacturing, distribution and allocation of available stock. The government acknowledged the impact of the shortage on regional communities. The company is working to restore supply and expects manufacturing constraints to ease as operations transition to two new facilities in Melbourne.

Until supplies return, the shortage presents a challenge for people at increased risk of infection. Healthcare providers and affected industries will need to manage limited availability carefully while awaiting the next vaccine batches.